O-134 Cochrane review on the effect of pentoxifylline for endometriosis

AbstractStudy questionTo assess the effect of pentoxifylline, a methyl-xanthine with anti-inflammatory effects, for the management of premenopausal women with endometriosis.Summary answerThere is not enough evidence to support the use of pentoxifylline in the management of premenopausal women with endometriosis to improve fertility and pain outcomes.What is known alreadyEndometriosis is a chronic, inflammatory condition that occurs mainly during the reproductive years. It is characterized by endometrium-like tissue developing outside the uterine cavity. This endometriotic tissue development is dependent on estrogen produced primarily by the ovaries and partially by the endometriotic tissue itself and, therefore, hormonal management is traditionally used. In light of the body of evidence suggesting an immunological component to the pathophysiology of endometriosis, the anti-inflammatory agent pentoxifylline has been proposed as an alternative therapeutic agent.Study design, size, durationA Cochrane systematic review and meta analysis was performed. Electronic searches of the Cochrane Gynaecology and Fertility Specialised Register of Controlled Searches, CENTRAL, MEDLINE, EMBASE, PsycINFO, CINAHL and AMED OVID were conducted to December 2020 to identify relevant randomised controlled trials (RCTs). In addition, electronic searches were conducted on the Epistemonikos database, Human Reproduction, Web of Knowedlge, OpenGrey, LILACS, Pubmed and Google.Participants/materials, setti...
Source: Human Reproduction - Category: Reproduction Medicine Source Type: research